Observation on the effect of adefovir dipivixil combined with thymosin α1 in the treatment of chronic hepatitis B

OBJECTIVE To observe the treatment effect of adefovir dipivixil in combination with thymosin α1 on chronic hepatitis B.METHODS The 102 patients with chronic hepatitis B were divided into two groups randomly. The treated group of 51 patients was treated by subcutaneous injection of thymosin α1 1.6 mg twice per week for 6 months in combination with taking adefovir dipivixil 10 mg per day for 12 months while the controlled group was treated with single adefovir dipivixil with same dose and therapy methods and period of treatment. The aim of this study was to measure the symptom, liver function, hepatitis B virus marker and viral replication indexes in hepatitis B before and after treatment.RESULTS At week 6, on ALT normalization and on removing HBV DNA, the treated group was compared with the controlled group P0.05. At end of treatment, there was no significant difference. On HBVDNA negative changing rate and HBeAg seroconversion, after comparison, P0.05; On clinical treatment effect, the curing rate of the treated group and the controlled group were 88% and 80% respectively, with no significant difference.CONCLUSION The combination treatment of adefovir dipivixil and thymosin α1 is effective on chronic hepatitis B by inhibiting virus replication rapidly, relieving liver inflammation,improving liver function and clinical symptom.